Get the Stockscreener App
10.15
2.50%
-0.26
Polyrizon Ltd stock is traded at $10.15, with a volume of 51,959.
It is down -2.50% in the last 24 hours and down -10.89% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. The company's technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$10.41
Open:
$10.31
24h Volume:
51,959
Relative Volume:
1.85
Market Cap:
$24.65M
Revenue:
Net Income/Loss:
$-3.34M
P/E Ratio:
-3.76
EPS:
-2.6995
Net Cash Flow:
$-10.54M
1W Performance:
+14.43%
1M Performance:
-10.89%
6M Performance:
-8.89%
1Y Performance:
+51.04%
1-Day Range:
$9.8001
$10.68
1-Week Range:
$8.00
$11.58
52-Week Range:
$2.88
$18.20
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
10.15 | 24.65M | 0 | -3.34M | -10.54M | -2.6995 |
VRTX
Vertex Pharmaceuticals Inc
|
508.13 | 128.79B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.40 | 95.18B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
798.88 | 82.25B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.25 | 53.66B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Polyrizon Ltd Stock (PLRZ) Latest News
A 9.99% ownership limit restricts exercise of Polyrizon (PLRZ) share purchase rights. - Stock Titan
First human trial gets approval as Polyrizon (PLRZ) reports a wider six-month loss. - Stock Titan
Single investor clears new Polyrizon (PLRZ) shares to resell - Stock Titan
Biotech Polyrizon (PLRZ) completes new warrant funding - Stock Titan
Polyrizon (NASDAQ: PLRZ) Announces Offering of 232,500 Shares at $12.00 Plus 30,000 Pre-Funded Warrants - kalkinemedia.com
Polyrizon announces closing of registered direct offering - Medical Buyer
Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement - The Globe and Mail
Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement - TipRanks
Single investor funds new Polyrizon (PLRZ) cash raise - Stock Titan
Polyrizon Ltd. (PLRZ) Stock: Company Closes $4 Million Deal With Institutional Investor - blockonomi.com
Polyrizon Ltd. Closes $4 Million Registered Direct Offering and Concurrent Private Placement - Quiver Quantitative
One investor puts about $4 million into Polyrizon - Stock Titan
Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement - TipRanks
$4M funding deal gives Polyrizon (PLRZ) investor long-term warrant rights - Stock Titan
Polyrizon Ltd. Closes $4 Million Registered Direct Offering and Concurrent Private Placement - Quiver Quantitative
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement - Yahoo Finance
Polyrizon raises $4 million in registered direct offering By Investing.com - Investing.com Nigeria
Polyrizon raises $4 million in registered direct offering By Investing.com - Investing.com South Africa
Polyrizon raises $4 million in registered direct offering - Investing.com
One investor agreed to buy Polyrizon shares and warrants; proceeds are expected at about $4 million. - Stock Titan
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement - Yahoo Finance
Polyrizon completes contracting for allergy blocker trial sites By Investing.com - Investing.com South Africa
Polyrizon Tumbles on Clinical Studies - Baystreet.ca
Polyrizon completes contracting for allergy blocker trial sites - Investing.com
Polyrizon Completes U.S. Clinical Site Contracting for NASARIX Allergy Blocker Study - Quiver Quantitative
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study - FinancialContent
Polyrizon completes contracting for allergy blocker trial sites By Investing.com - Investing.com UK
Polyrizon Tumbles on Clinical Studies - Baystreet.ca
Polyrizon (PLRZ) Trading: Ends Down by 1.40% at $10.53 in Latest Trading; the Current Price Sits Inside the Supplied Technical Range in the Latest SessionAnalyst Downgrade Signals - vinanet.vn
Polyrizon (PLRZ) Trading: Ends Down by 1.40% at $10.53 in Latest Trading; the Current Price Sits Inside the Supplied Technical Range in the Latest SessionVWAP Breakout - careplusvn.com
Polyrizon (PLRZ) Trading: Ends Down by 1.40% at $10.53 in Latest Trading; the Current Price Sits Inside the Supplied Technical Range in the Latest SessionSchiff Line - dars.gov.et
Polyrizon (PLRZ) Trading: Ends Down by 1.40% at $10.53 in Latest Trading; the Current Price Sits Inside the Supplied Technical Range in the Latest SessionMutual Fund Flow - dars.gov.et
Polyrizon (PLRZ) Trading: Ends Down by 1.40% at $10.53 in Latest Trading; the Current Price Sits Inside the Supplied Technical Range in the Latest SessionTake Profit Levels - dars.gov.et
Polyrizon (PLRZ) Trading: Ends Down by 1.40% at $10.53 in Latest Trading; the Current Price Sits Inside the Supplied Technical Range in the Latest SessionOverbought Signal Alerts - https://www.dars.gov.et/
Polyrizon (PLRZ) Latest: Closes 6.26% Lower at $10.49 in the Current Update; Range Check: Support at $9.97 and Resistance at $11.01 Frame the Range in Latest TradingWyckoff Accumulation - vinanet.vn
Polyrizon Finalizes U.S. Clinical Site Network for NASARIX Allergy Study - TipRanks
Polyrizon (PLRZ) lines up sites for 120-patient allergy study - Stock Titan
Polyrizon completes contracting with all five clinical sites By Investing.com - Investing.com South Africa
Polyrizon completes contracting with all five clinical sites By Investing.com - Investing.com Nigeria
Polyrizon completes contracting with all five clinical sites By Investing.com - Investing.com India
Polyrizon completes contracting with all five clinical sites By Investing.com - Investing.com Canada
Polyrizon Completes Site Contracting for NASARIX™ Seasonal Allergic Rhinitis Study - Quiver Quantitative
Polyrizon's planned allergy study will compare its spray with saline in up to 120 patients - Stock Titan
Polyrizon (PLRZ) Latest: Closes 6.26% Lower at $10.49 in the Current Update; Range Check: Support at $9.97 and Resistance at $11.01 Frame the Range in Latest TradingUnusual Put Volume - careplusvn.com
Polyrizon (PLRZ) Latest: Closes 6.26% Lower at $10.49 in the Current Update; Range Check: Support at $9.97 and Resistance at $11.01 Frame the Range in Latest TradingHedge Fund Favorites - dars.gov.et
Polyrizon (PLRZ) Latest: Closes 6.26% Lower at $10.49 in the Current Update; Range Check: Support at $9.97 and Resistance at $11.01 Frame the Range in Latest TradingLeveraged ETF Flow - dars.gov.et
Polyrizon (PLRZ) Latest: Closes 6.26% Lower at $10.49 in the Current Update; Range Check: Support at $9.97 and Resistance at $11.01 Frame the Range in Latest TradingTrend Following Picks - dars.gov.et
Polyrizon (PLRZ) Latest: Closes 6.26% Lower at $10.49 in the Current Update; Range Check: Support at $9.97 and Resistance at $11.01 Frame the Range in Latest TradingTriple MA Cross - www.dars.gov.et
Polyrizon (PLRZ) Latest: Closes 6.26% Lower at $10.49 in the Current Update; Range Check: Support at $9.97 and Resistance at $11.01 Frame the Range in Latest TradingGrowth ETF - dars.gov.et
Polyrizon (PLRZ) Close and Levels: Records a 5.65% Decrease to $10.36 for the Current Session; Nearby Levels: the Current Price Sits Inside the Supplied Technical Range in the Available RecordRectangle Pattern - vinanet.vn
Polyrizon Ltd Stock (PLRZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Polyrizon Ltd Stock (PLRZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Adler Oz | Director |
Mar 31 '26 |
Sale |
12.05 |
3,292 |
39,669 |
19,850 |
| Carmel Liron | Director |
Mar 31 '26 |
Sale |
12.36 |
942 |
11,643 |
3,127 |
| Carmel Liron | Director |
Mar 30 '26 |
Sale |
11.00 |
100 |
1,100 |
4,069 |
| Izraeli Tomer | Chief Executive Officer |
Mar 30 '26 |
Sale |
10.90 |
3,900 |
42,510 |
32,012 |
| Turgeman Tidhar | Chief Technology Officer |
Mar 30 '26 |
Sale |
10.90 |
2,917 |
31,795 |
17,518 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):